Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current

News

Ionis Pharmaceuticals Says Topline Results From The Pivotal Study Of Zilganersen For Alexander Disease Showed Statistically Significant And Clinically Meaningful Stabilization On The Primary Endpoint Of Gait Speed Compared To Control

Author: Benzinga Newsdesk | September 22, 2025 07:07am
  • First and only investigational medicine to demonstrate a clinically meaningful and disease-modifying impact on this rare, often fatal neurological condition.
  • NDA submission planned in Q1 2026

Posted In: IONS

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist